Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06528314 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
A Phase 3 study of NASH - Nonalcoholic Steatohepatitis and MASH - Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Akero Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
- 20
- Study locations
NCT06528314 is a Phase 3 study of NASH - Nonalcoholic Steatohepatitis and MASH - Metabolic Dysfunction-Associated Steatohepatitis that is actively recruiting participants, run by Akero Therapeutics. The registered enrollment target is 1,150 participants, above the 226-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (409% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06528314, a Phase 3 study of NASH - Nonalcoholic Steatohepatitis and MASH - Metabolic Dysfunction-Associated Steatohepatitis, is actively recruiting participants, sponsored by Akero Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Efruxifermin
Study Locations (20)
Arizona
- Akero Clinical Study Site - Chandler
- Akero Clinical Study Site - Flagstaff
- Akero Clinical Study Site - Peoria
- Akero Clinical Study Site - Scottsdale
- Akero Clinical Study Site - Tucson
- Akero Clinical Study Site - Tucson
- Akero Clinical Study Site - Tucson
- Akero Clinical Study Site - Tucson
California
- Akero Clinical Study Site - Coronado
- Akero Clinical Study Site - Escondido
- Akero Clinical Study Site - Folsom
- Akero Clinical Study Site - Lancaster
- Akero Clinical Study Site - Long Beach
- Akero Clinical Study Site - Los Angeles
Arkansas
- Akero Clinical Study Site - Conway
- Akero Clinical Study Site - Jonesboro
- Akero Clinical Study Site - Little Rock
- Akero Clinical Study Site - North Little Rock
Alabama
- Akero Clinical Study Site - Birmingham
- Akero Clinical Study Site - Dothan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2029-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06528314
The ClinicalTrials.gov registry entry for NCT06528314 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 226-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (409% higher). The listed sponsor is Akero Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06528314 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Arizona, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06528314 about?
NCT06528314 is a clinical study titled "A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH". This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
What is the current status of trial NCT06528314?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2024-09-04. Estimated completion is 2029-10.
What conditions does trial NCT06528314 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis.
What interventions are being tested in trial NCT06528314?
The interventions under investigation include: Placebo (DRUG), Efruxifermin (DRUG).
Who is sponsoring clinical trial NCT06528314?
This trial is sponsored by Akero Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06528314 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
RECRUITING · Phase 3
-
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
ACTIVE NOT RECRUITING · Phase 3
-
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
RECRUITING
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
Explore more on PlainTrial
NASH - Nonalcoholic Steatohepatitis
All registered trials for this condition
MASH - Metabolic Dysfunction-Associated Steatohepatitis
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.